Advertisement

AIDS and Behavior

, Volume 22, Supplement 1, pp 10–18 | Cite as

Syringe Sharing in Drug Injecting Dyads: A Cross-Classified Multilevel Analysis of Social Networks

  • Armita Shahesmaeili
  • Ali Mirzazadeh
  • Willi McFarland
  • Hamid Sharifi
  • Ali Akbar Haghdoost
  • Hamid Soori
Original Paper

Abstract

We examined the association of dyadic-level factors with syringe sharing among people who inject drugs (PWID) in Kerman, Iran. In a cross-sectional study, we collected data on 329 drug-injecting dyads by individual face-to-face interviews. An injecting dyad was defined as 2 PWID who knew each other and injected drugs together during the last 6 months. If they reported at least 1 occasion of syringe sharing, the dyad was considered high-risk. Dyadic-level factors associated with syringe sharing were assessed using cross-classified multilevel logistic regression. The rate of syringe sharing was significantly higher for dyads who were more intimate (adjusted odds ratio [AOR] 4.5, CI 95%, 2.3–8.6), who had instrumental support (AOR 2.1, 95% CI 1.1–4.5), and who pooled money for drugs (AOR 4.1, 95% CI 2.0–8.3). The rate was lower in same-sex dyads (AOR 0.4, 95% CI 0.2–0.9) and in dyads who shared health information (AOR 0.5, 95% CI 0.2–0.9). Findings highlight close-peer influences on syringe-sharing behavior.

Keywords

Dyad Syringe sharing People who inject drugs Iran 

Notes

Acknowledgements

We wish to acknowledge support from the University of California, San Francisco’s International Traineeships in AIDS Prevention Studies (ITAPS), U.S. NIMH, R25MH064712. We also wish to thank Mr. Masoud Izadpanah and Mrs. Baghizadeh for their efforts in interviews and data collection.

Funding

The study was funded by Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Compliance with Ethical Standards

Conflict of interest

All authors declare that they have no conflict of interest.

Ethical Approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed Consent

Informed consent was obtained from all individual participants included in the study. PWIDs were given 80,000 rialsa (equal to ~ 2.67 USD) primary incentive (80,000 Iranian rials, or ~ 2.67 USD) as an incentive for participating in the study and 30,000 Rials (equal to ~ 1 USD) for each successful recruitment of an injecting peer. The study protocol was reviewed and approved by the Ethics Committee of Shahid Beheshti University of Medical Sciences.

References

  1. 1.
    Nikfarjam A, Shokoohi M, Shahesmaeili A, Haghdoost AA, Baneshi MR, Haji-Maghsoudi S, et al. National population size estimation of illicit drug users through the network scale-up method in 2013 in Iran. Int J Drug Policy. 2016;31:147–52.CrossRefPubMedGoogle Scholar
  2. 2.
    Amiri FB, Mostafavi E, Mirzazadeh A. HIV, HBV and HCV coinfection prevalence in Iran—a systematic review and meta-analysis. PLoS ONE. 2016;11(3):e0151946.CrossRefGoogle Scholar
  3. 3.
    Mumtaz GR, Weiss HA, Thomas SL, Riome S, Setayesh H, Riedner G, et al. HIV among people who inject drugs in the Middle East and North Africa: systematic review and data synthesis. PLoS Med. 2014;11(6):e1001663.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Khajehkazemi R, Osooli M, Sajadi L, Karamouzian M, Sedaghat A, Fahimfar N, et al. HIV prevalence and risk behaviours among people who inject drugs in Iran: the 2010 National Surveillance Survey. Sex Transm Infect. 2013;89(Suppl 3):29–32.CrossRefGoogle Scholar
  5. 5.
    Pasa MK, Alom KR, Bashri Z, Vermund SH. Sharing of needles and syringes among men who inject drugs: HIV risk in Northwest Bangladesh. PLoS ONE. 2016;11(2):e0148276.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Otiashvili D, Latypov A, Kirtadze I, Ibragimov U, Zule W. Drug preparation, injection, and sharing practices in Tajikistan: a qualitative study in Kulob and Khorog. Subst Abuse Treat Prev Policy. 2016;11(1):21.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Beletsky L, Heller D, Jenness SM, Neaigus A, Gelpi-Acosta C, Hagan H. Syringe access, syringe sharing, and police encounters among people who inject drugs in New York City: a community-level perspective. Int J Drug Policy. 2014;25(1):105–11.CrossRefPubMedGoogle Scholar
  8. 8.
    Rhodes T, Mikhailova L, Sarang A, Lowndes CM, Rylkov A, Khutorskoy M, et al. Situational factors influencing drug injecting, risk reduction and syringe exchange in Togliatti City, Russian Federation: a qualitative study of micro risk environment. Soc Sci Med. 2003;57(1):39–54.CrossRefPubMedGoogle Scholar
  9. 9.
    Ahmed T, Long TN, Huong PT, Stewart DE. Drug injecting and HIV risk among injecting drug users in Hai Phong, Vietnam: a qualitative analysis. BMC Public Health. 2015;15(1):32.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Thanh DC, Moland KM, Fylkesnes K. The context of HIV risk behaviours among HIV-positive injection drug users in Viet Nam: moving toward effective harm reduction. BMC Public Health. 2009;9(1):98.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Himmich H, Madani N. The state of harm reduction in the Middle East and North Africa: a focus on Iran and Morocco. Int J Drug Policy. 2016;31:184–9.CrossRefPubMedGoogle Scholar
  12. 12.
    Alam Mehrjerdi Z, Noori R, Dolan K. Opioid use, treatment and harm reduction services: the first report from the Persian Gulf region. J Subst Use. 2015;1–7.Google Scholar
  13. 13.
    Khajehkazemi R, Osooli M, Sajadi L, Karamouzian M, Sedaghat A, Fahimfar N, et al. HIV prevalence and risk behaviours among people who inject drugs in Iran: the 2010 National Surveillance Survey. Sex Transm Infect. 2013;1–4.Google Scholar
  14. 14.
    Kazerooni A, Joolaei H, Parsa N. Knowledge and attitude of male intravenous drug users on HIV/AIDS associated high risk behaviors in Shiraz Pir-Banon jail, Fars Province, Southern Iran. Iranian Red Crescent Med J. 2010;12(3):334–6.Google Scholar
  15. 15.
    Rezaie F, Farhadi MH, Farhoudian A, Najafi M, Bazrafshan A, Higgs P, et al. Access to needle and syringe programs and the relationship to equipment sharing among people who inject drugs in Kermanshah, Iran. J Subst Use. 2016;1–6.Google Scholar
  16. 16.
    Nazari SSH, Noroozi M, Soori H, Noroozi A, Mehrabi Y, Hajebi A, et al. The effect of on-site and outreach-based needle and syringe programs in people who inject drugs in Kermanshah, Iran. Int J Drug Policy. 2016;27:127–31.CrossRefPubMedGoogle Scholar
  17. 17.
    Amin-Esmaeili M, Rahimi-Movaghar A, Gholamrezaei M, Razaghi EM. Profile of people who inject drugs in Tehran, Iran. Acta Medica Iranica. 2017;54(12):793–805.Google Scholar
  18. 18.
    Habibi M, Farmanfarmaee S, Darharaj M, Khoshnood K, Matacotta JJ, O’Bryan J. Predictors of HIV risk behavior in iranian women who inject drugs. J Drug Issues. 2017;0022042617693383.Google Scholar
  19. 19.
    Noori R, Narenjiha H, Aghabakhshi H, Habibi G, Khoshkrood Mansoori B. Methadone maintenance therapy outcomes in Iran. Subst Use Misuse. 2012;47(7):767–73.CrossRefPubMedGoogle Scholar
  20. 20.
    Galea S, Riddle M, Kaplan GA. Causal thinking and complex system approaches in epidemiology. Int J Epidemiol. 2010;39(1):97–106.CrossRefPubMedGoogle Scholar
  21. 21.
    Luke DA, Harris JK. Network analysis in public health: history, methods, and applications. Annu Rev Public Health. 2007;28:69–93.CrossRefPubMedGoogle Scholar
  22. 22.
    Sherman SG, Latkin CA, Gielen AC. Social factors related to syringe sharing among injecting partners: a focus on gender. Subst Use Misuse. 2001;36(14):2113–36.CrossRefPubMedGoogle Scholar
  23. 23.
    Friedman SR, Curtis R, Neaigus A, Jose B, Des Jarlais DC. Social networks, drug injectors lives, and HIV/AIDS. Springer Science & Business Media; 2006.Google Scholar
  24. 24.
    Morris MD, Bates A, Andrew E, Hahn J, Page K, Maher L. More than just someone to inject drugs with: injecting within primary injection partnerships. Drug Alcohol Depend. 2015;156:275–81.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Gyarmathy VA, Li N, Tobin KE, Hoffman IF, Sokolov N, Levchenko J, et al. Injecting equipment sharing in Russian drug injecting dyads. AIDS Behav. 2010;14(1):141–51.CrossRefPubMedGoogle Scholar
  26. 26.
    O’Malley AJ. The analysis of social network data: an exciting frontier for statisticians. Stat Med. 2013;32(4):539–55.CrossRefPubMedGoogle Scholar
  27. 27.
    McMahon JM, Pouget ER, Tortu S. A guide for multilevel modeling of dyadic data with binary outcomes using SAS PROC NLMIXED. Comput Stat Data Anal. 2006;50(12):3663–80.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Leckie G. Module 12: cross-classified multilevel models. LEMMA online course: University of Bristol, Centre for Multilevel Modelling; 2013.Google Scholar
  29. 29.
    Fielding A, Goldstein H. Cross-classified and multiple membership structures in multilevel models: an introduction and review; 2006.Google Scholar
  30. 30.
    Wikipedia. Kerman 2017. Available from: https://en.wikipedia.org/wiki/Kerman.
  31. 31.
    Shokoohi M, Baneshi MR, Ali-akbar H. Size estimation of groups at high risk of HIV/AIDS using network scale up in Kerman, Iran. Int J Prev Med. 2012;3(7):471–6.PubMedPubMedCentralGoogle Scholar
  32. 32.
    Friedman SR, Curtis R, Neaigus A, Jose B, Des Jarlais DC. Syringe sharing and the social characteristics of drug-injecting dyads. Social Networks, Drug Injectors’ Lives, and HIV/AIDS; 2002. p. 143–56.Google Scholar
  33. 33.
    Khajehkazemi R, Haghdoost A, Navadeh S, Setayesh H, Sajadi L, Osooli M, et al. Risk and vulnerability of key populations to HIV infection in Iran; knowledge, attitude and practises of female sex workers, prison inmates and people who inject drugs. Sexual Health. 2014;11(6):568–74.CrossRefPubMedGoogle Scholar
  34. 34.
    Rahnama R, Mohraz M, Mirzazadeh A, Rutherford G, McFarland W, Akbari G, et al. Access to harm reduction programs among persons who inject drugs: findings from a respondent-driven sampling survey in Tehran, Iran. Int J Drug Policy. 2014;25(4):717–23.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Jahanbakhsh F, Mostafavi E, Haghdoost A. The potential for HIV self-testing in Iran. Int J Prev Med. 2016;6(114).Google Scholar
  36. 36.
    Shahesmaeili A, Haghdoost AA, Soori H. Network location and risk of human immunodeficiency virus transmission among injecting drug users: results of multiple membership multilevel modeling of social networks. Addiction Health. 2015;7(1–2):1–13.PubMedPubMedCentralGoogle Scholar
  37. 37.
    De P, Cox J, Boivin J-F, Platt RW, Jolly AM. The importance of social networks in their association to drug equipment sharing among injection drug users: a review. Addiction. 2007;102(11):1730–9.CrossRefPubMedGoogle Scholar
  38. 38.
    Loxley W, Ovenden C. Friends and lovers: needle sharing in young people in Western Australia. AIDS Care. 1995;7(3):337–52.CrossRefPubMedGoogle Scholar
  39. 39.
    Latkin CA, Sherman S, Knowlton A. HIV prevention among drug users: outcome of a network-oriented peer outreach intervention. Health Psychol. 2003;22(4):332.CrossRefPubMedGoogle Scholar
  40. 40.
    Cepeda JA, Odinokova VA, Heimer R, Grau LE, Lyubimova A, Safiullina L, et al. Drug network characteristics and HIV risk among injection drug users in Russia: the roles of trust, size, and stability. AIDS Behav. 2011;15(5):1003–10.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Shaw SY, Shah L, Jolly AM, Wylie JL. Determinants of injection drug user (IDU) syringe sharing: the relationship between availability of syringes and risk network member characteristics in Winnipeg, Canada. Addiction. 2007;102(10):1626–35.CrossRefPubMedGoogle Scholar
  42. 42.
    Koester S, Glanz J, Barón A. Drug sharing among heroin networks: implications for HIV and hepatitis B and C prevention. AIDS Behav. 2005;9(1):27–39.CrossRefPubMedGoogle Scholar
  43. 43.
    Grund JP, Kaplan CD, Adriaans NF, Blanken P. Drug sharing and HIV transmission risks: the practice of frontloading in the Dutch injecting drug user population. J Psychoact Drugs 1991;23(1):1–10Google Scholar
  44. 44.
    El-Bassel N, Shaw SA, Dasgupta A, Strathdee SA. People who inject drugs in intimate relationships: it takes two to combat HIV. Curr HIV/AIDS Rep. 2014;11(1):45–51.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Grund J-PC, Friedman SR, Stern LS, Jose B, Neaigus A, Curtis R, et al. Syringe-mediated drug sharing among injecting drug users: patterns, social context and implications for transmission of blood-borne pathogens. Soc Sci Med. 1996;42(5):691–703.Google Scholar
  46. 46.
    Booth RE, Lehman WE, Latkin CA, Dvoryak S, Brewster JT, Royer MS, et al. Individual and network interventions with injection drug users in 5 Ukraine cities. Am J Public Health. 2011;101(2):336–43.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Smyrnov P, Williams LD, Korobchuk A, Sazonova Y, Nikolopoulos GK, Skaathun B, et al. Risk network approaches to locating undiagnosed HIV cases in Odessa, Ukraine. J Int AIDS Soc. 2018;21(1):e25040.CrossRefPubMedCentralGoogle Scholar
  48. 48.
    Nikolopoulos GK, Pavlitina E, Muth SQ, Schneider J, Psichogiou M, Williams LD, et al. A network intervention that locates and intervenes with recently HIV-infected persons: the Transmission Reduction Intervention Project (TRIP). Sci Rep. 2016;6:38100.CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Latkin CA, Smith MK, Ha TV, Mo TT, Zelaya C, Sripaipan T, et al. Roles and functions of social networks among men who use drugs in ART initiation in Vietnam. AIDS Behav. 2016;20(11):2782–9.CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Marshall Z, Dechman M, Minichiello A, Alcock L, Harris G. Peering into the literature: a systematic review of the roles of people who inject drugs in harm reduction initiatives. Drug Alcohol Depend. 2015;151:1–14.CrossRefPubMedGoogle Scholar
  51. 51.
    Smyrnov P, Williams LD, Korobchuk A, Sazonova Y, Nikolopoulos GK, Skaathun B, et al. Risk network approaches to locating undiagnosed HIV cases in Odessa, Ukraine. J Int AIDS Soc. 2018;21(1).Google Scholar
  52. 52.
    Hosseini Hooshyar S, Ranjbar E, Sharifi H, Shafiei M, Tayeri K, Haghdoost A, et al. Evaluating the HIV continuum of care and treatment in a low prevalence city in Iran: Kerman HIV-Friendly City initiative. East Afr J Appl Health Monit Eval. 2018(2).Google Scholar
  53. 53.
    Medley A, Kennedy C, O’Reilly K, Sweat M. Effectiveness of peer education interventions for HIV prevention in developing countries: a systematic review and meta-analysis. AIDS Educ Prev. 2009;21(3):181–206.CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Simoni JM, Nelson KM, Franks JC, Yard SS, Lehavot K. Are peer interventions for HIV efficacious? A systematic review. AIDS Behav. 2011;15(8):1589–95.CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    Valente TW, Gallaher P, Mouttapa M. Using social networks to understand and prevent substance use: a transdisciplinary perspective. Subst Use Misuse. 2004;39(10–12):1685–712.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Armita Shahesmaeili
    • 1
  • Ali Mirzazadeh
    • 1
    • 2
  • Willi McFarland
    • 2
  • Hamid Sharifi
    • 1
  • Ali Akbar Haghdoost
    • 3
  • Hamid Soori
    • 4
  1. 1.HIV/STI Surveillance Research Center, and WHO Collaborating Center for HIV Surveillance, Institute for Futures Studies in HealthKerman University of Medical SciencesKermanIran
  2. 2.Department of Epidemiology and BiostatisticsUniversity of California San FranciscoSan FranciscoUSA
  3. 3.Modeling in Health Research Center, Institute for Futures Studies in HealthKerman University of Medical SciencesKermanIran
  4. 4.Safety Promotion and Injury Prevention Research Center, School of Public HealthShahid Beheshti University of Medical SciencesTehranIran

Personalised recommendations